ReviewPolymers2025
Toward Sustainable Polyhydroxyalkanoates: A Next-Gen Biotechnology Approach.
Review in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Polyhydroxybutyrate (PHB): Production, Properties, Modification Strategies, Additive Manufacturing, Biodegradation, and Applications.Materials (Basel, Switzerland) · 2026Review
- Advances in Polyhydroxyalkanoate (PHA) Production, Volume 4.Bioengineering (Basel, Switzerland) · 2026Article
- Bioprospecting Sambhar lake haloalkaliphiles for polyhydroxyalkanoates production.Archives of microbiology · 2026Article
- Insights into transcriptional expression and putative functions of multiple polyhydroxyalkanoate synthase paralogs in Haloferax mediterranei.FEMS microbiology letters · 2026Article
- Active bio-packaging with PHBHHx-ZnO bionanocomposites: advancing food safety and shelf-life.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polyhydroxyalkanoates (PHAs) are biodegradable biopolymers synthesized by microorganisms and serve as sustainable alternatives to petroleum-based plastics. While traditional PHA production relies on refined carbon sources and pure cultures, high costs and scalability challenges limit commercial viability. Extremophiles, particularly halophiles, have emerged as promising candidates for cost-effective, large-scale production of PHAs. Their ability to thrive in extreme environments reduces contamination risks, minimizes the need for sterilization, and lowers operational costs. Advancements in metabolic engineering, synthetic biology, and CRISPR-based genome editing have enhanced PHA yields by optimizing metabolic flux and cell morphology. Additionally, utilizing alternative feedstocks such as biowaste, syngas, methane, and CO₂ improves economic feasibility. Next-generation industrial biotechnology integrates extremophilic microbes with AI-driven fermentation and eco-friendly downstream processing to enhance scalability. Industrial-scale production of PHAs using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.